DSpace at RU >

Browsing by Author Ruxrungtham, K.

Full Text	Issue Date	Title	Author(s)
	2011	Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.	Ramautarsing, R.A.; Lugt, J. van der; Gorowara, M.; Kerr, S.J.; Burger, D.M., et al
	2010	Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries.	Gorowara, M.; Burger, D.M.; Hill, A.; Ruxrungtham, K.
	2009	The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.	Lugt, J. van der; Colbers, A.; Molto, J.; Hawkins, D.; Ende, M. van der, et al
	2009	A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.	Avihingsanon, A.; Lugt, J. van der; Kerr, S.J.; Gorowara, M.; Chanmano, S., et al
	2009	Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.	Lugt, J. van der; Gorowara, M.; Avihingsanon, A.; Burger, D.M.; Ananworanich, J., et al
	2009	Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.	Puthanakit, T.; Lugt, J. van der; Bunupuradah, T.; Ananworanich, J.; Gorowara, M., et al
	2009	Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.	Lugt, J. van der; Lange, J.; Avihingsanon, A.; Ananworanich, J.; Sealoo, S., et al
	2009	Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.	Bunupuradah, T.; Lugt, J. van der; Kosalaraksa, P.; Engchanil, C.; Boonrak, P., et al
	2008	Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.	Kosalaraksa, P.; Bunupuradah, T.; Engchanil, C.; Boonrak, P.; Intasan, J., et al
	2008	Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.	Avihingsanon, A.; Manosuthi, W.; Kantipong, P.; Chuchotaworn, C.; Moolphate, S., et al
	2008	Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.	Lugt, J. van der; Autar, R.S.; Ubolyam, S.; Garcia, E.F.; Sankote, J., et al
	2007	Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.	Autar, R.S.; Wit, F.W.; Sankote, J.; Sutthichom, D.; Kimenai, E., et al
	2006	The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.	Boyd, M.A.; Siangphoe, U.; Ruxrungtham, K.; Reiss, P.; Mahanontharit, A., et al
	2006	Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).	Boyd, M.A.; Srasuebkul, P.; Khongphattanayothin, M.; Ruxrungtham, K.; Hassink, E.A.M., et al
	2005	Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.	Autar, S.R.; Wit, F.W.; Sankote, J.; Mahanontharit, A.; Anekthananon, T., et al
	2005	Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.	Ananworanich, J.; Kosalaraksa, P.; Hill, A.; Siangphoe, U.; Bergshoeff, A.S., et al
	2005	Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.	Boyd, M.; Mootsikapun, P.; Burger, D.M.; Chuenyam, T.; Ubolyam, S., et al
	2004	Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.	Autar, R.S.; Ananworanich, J.; Apateerapong, W.; Sankote, J.; Hill, A., et al